Psoriatic Arthritis

August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.

Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.

We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.

We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.

With structural inhibition now in the label, Mease explains why radiographic protection matters as a treatment goal and what it means to have that evidence for an IL-23 inhibitor.

Iain McInnes, MD, PhD, discussed comparing bimekizumab and risankizumab for PsA.

Philip Mease, MD, discusses BE BOLD, which delivers the first head-to-head superiority result for a joint-focused endpoint in psoriatic arthritis.

Phase 2b/3 data show durable ACR50/70, PASI90/100, and minimal disease activity responses with izokibep through one year.

Guselkumab (Tremfya) was originally approved in 2020, with its indication expanded to pediatric patients with psoriatic arthritis in 2025.

Findings will be presented at the EULAR Annual Meeting and show significantly more bimekizumab-treated patients achieved the 16 week ACR50 primary endpoint.

Real-world data suggest IL-23 biologics may cut 3-year psoriatic arthritis risk in psoriasis versus TNF and IL-17 therapies.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Additional data from the BE BOLD trial supporting bimekizumab over risankizumab are slated for a future medical conference.

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

Full data from BE BOLD supporting bimekizumab over risankizumab are expected at a future medical meeting.

The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.

Ruderman discussed the topics of his year in review talks at RWCS 2026.

This rheumatology month in review emphasizes new data and FDA actions.

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

This rheumatology month in review emphasizes new data and impactful approvals.